Original Research
7 March 2017

Cytokine Inhibition in Patients With Chronic Fatigue Syndrome: A Randomized Trial

Publication: Annals of Internal Medicine
Volume 166, Number 8

Abstract

Background:

Interleukin-1 (IL-1), an important proinflammatory cytokine, is suspected to play a role in chronic fatigue syndrome (CFS).

Objective:

To evaluate the effect of subcutaneous anakinra versus placebo on fatigue severity in female patients with CFS.

Design:

Randomized, placebo-controlled trial from July 2014 to May 2016. Patients, providers, and researchers were blinded to treatment assignment. (ClinicalTrials.gov: NCT02108210)

Setting:

University hospital in the Netherlands.

Patients:

50 women aged 18 to 59 years with CFS and severe fatigue leading to functional impairment.

Intervention:

Participants were randomly assigned to daily subcutaneous anakinra, 100 mg (n = 25), or placebo (n = 25) for 4 weeks and were followed for an additional 20 weeks after treatment (n = 50).

Measurements:

The primary outcome was fatigue severity, measured by the Checklist Individual Strength subscale (CIS-fatigue) at 4 weeks. Secondary outcomes were level of impairment, physical and social functioning, psychological distress, and pain severity at 4 and 24 weeks.

Results:

At 4 weeks, 8% (2 of 25) of anakinra recipients and 20% (5 of 25) of placebo recipients reached a fatigue level within the range reported by healthy persons. There were no clinically important or statistically significant differences between groups in CIS-fatigue score at 4 weeks (mean difference, 1.5 points [95% CI, −4.1 to 7.2 points]) or the end of follow-up. No statistically significant between-group differences were seen for any secondary outcome at 4 weeks or the end of follow-up. One patient in the anakinra group discontinued treatment because of an adverse event. Patients in the anakinra group had more injection site reactions (68% [17 of 25] vs. 4% [1 of 25]).

Limitation:

Small sample size and wide variability in symptom duration; inclusion was not limited to patients with postinfectious symptoms.

Conclusion:

Peripheral IL-1 inhibition using anakinra for 4 weeks does not result in a clinically significant reduction in fatigue severity in women with CFS and severe fatigue.

Primary Funding Source:

Interleukin Foundation and an independent donor who wishes to remain anonymous.

Get full access to this article

View all available purchase options and get full access to this article.

Supplemental Material

Supplement. Study Protocol

References

1.
Fukuda KStraus SEHickie ISharpe MCDobbins JGKomaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121:953-9. [PMID: 7978722].  doi: 10.7326/0003-4819-121-12-199412150-00009
2.
Reeves WCLloyd AVernon SDKlimas NJason LABleijenberg Get alInternational Chronic Fatigue Syndrome Study Group. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Serv Res. 2003;3:25. [PMID: 14702202]
3.
Whiting PBagnall AMSowden AJCornell JEMulrow CDRamírez G. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review. JAMA. 2001;286:1360-8. [PMID: 11560542]
4.
Larun LBrurberg KGOdgaard-Jensen JPrice JR. Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev. 2015:CD003200. [PMID: 25674924]  doi: 10.1002/14651858.CD003200.pub3
5.
Price JRMitchell ETidy EHunot V. Cognitive behaviour therapy for chronic fatigue syndrome in adults. Cochrane Database Syst Rev. 2008:CD001027. [PMID: 18646067]  doi: 10.1002/14651858.CD001027.pub2
6.
Smith MEHaney EMcDonagh MPappas MDaeges MWasson Net al. Treatment of myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162:841-50. [PMID: 26075755].  doi: 10.7326/M15-0114
7.
Dantzer RO'Connor JCFreund GGJohnson RWKelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46-56. [PMID: 18073775]
8.
Bonsall DRKim HTocci CNdiaye APetronzio AMcKay-Corkum Get al. Suppression of locomotor activity in female C57Bl/6J mice treated with interleukin-1ß: investigating a method for the study of fatigue in laboratory animals. PLoS One. 2015;10:e0140678. [PMID: 26469939]  doi: 10.1371/journal.pone.0140678
9.
Nunes EJRandall PAEstrada AEpling BHart EELee CAet al. Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/chow feeding choice task. Psychopharmacology (Berl). 2014;231:727-36. [PMID: 24136220]  doi: 10.1007/s00213-013-3285-4
10.
Woodlock TJSahasrabudhe DMMarquis DMGreene DPandya KJMcCune CS. Active specific immunotherapy for metastatic colorectal carcinoma: phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha. J Immunother. 1999;22:251-9. [PMID: 10335485]
11.
Rinehart JHersh EIssell BTriozzi PBuhles WNeidhart J. Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940. Cancer Invest. 1997;15:403-10. [PMID: 9316621]
12.
Weisdorf DKatsanis EVerfaillie CRamsay NKHaake RGarrison Let al. Interleukin-1 alpha administered after autologous transplantation: a phase I/II clinical trial. Blood. 1994;84:2044-9. [PMID: 7915916]
13.
Walsh CELiu JMAnderson SMRossio JLNienhuis AWYoung NS. A trial of recombinant human interleukin-1 in patients with severe refractory aplastic anaemia. Br J Haematol. 1992;80:106-10. [PMID: 1536797]
14.
Felger JCMiller AH. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol. 2012;33:315-27. [PMID: 23000204]  doi: 10.1016/j.yfrne.2012.09.003
15.
Hornig MMontoya JGKlimas NGLevine SFelsenstein DBateman Let al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv. 2015;1. [PMID: 26079000]
16.
Swanink CMVercoulen JHGalama JMRoos MTMeyaard Lvan der Ven-Jongekrijg Jet al. Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome. J Infect Dis. 1996;173:460-3. [PMID: 8568312]
17.
Vollmer-Conna UCameron BHadzi-Pavlovic DSingletary KDavenport TVernon Set alDubbo Infective Outcomes Study Group. Postinfective fatigue syndrome is not associated with altered cytokine production. Clin Infect Dis. 2007;45:732-5. [PMID: 17712757]
18.
Blundell SRay KKBuckland MWhite PD. Chronic fatigue syndrome and circulating cytokines: a systematic review. Brain Behav Immun. 2015;50:186-95. [PMID: 26148446]  doi: 10.1016/j.bbi.2015.07.004
19.
Fletcher MAZeng XRBarnes ZLevis SKlimas NG. Plasma cytokines in women with chronic fatigue syndrome. J Transl Med. 2009;7:96. [PMID: 19909538]  doi: 10.1186/1479-5876-7-96
20.
Linde AAndersson BSvenson SBAhrne HCarlsson MForsberg Pet al. Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis. 1992;165:994-1000. [PMID: 1316417]
21.
Neu DMairesse OMontana XGilson MCorazza FLefevre Net al. Dimensions of pure chronic fatigue: psychophysical, cognitive and biological correlates in the chronic fatigue syndrome. Eur J Appl Physiol. 2014;114:1841-51. [PMID: 24878689]  doi: 10.1007/s00421-014-2910-1
22.
de Jager WBourcier KRijkers GTPrakken BJSeyfert-Margolis V. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol. 2009;10:52. [PMID: 19785746]  doi: 10.1186/1471-2172-10-52
23.
Lachmann HJLowe PFelix SDRordorf CLeslie KMadhoo Set al. In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes. J Exp Med. 2009;206:1029-36. [PMID: 19364880]  doi: 10.1084/jem.20082481
24.
Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095-147. [PMID: 8630372]
25.
Roerink MEvan der Schaaf MEDinarello CAKnoop Hvan der Meer JW. Interleukin-1 as a mediator of fatigue in disease: a narrative review. J Neuroinflammation. 2017;14:16. [PMID: 28109186]  doi: 10.1186/s12974-017-0796-7
26.
Dinarello CAvan der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25:469-84. [PMID: 24275598]  doi: 10.1016/j.smim.2013.10.008
27.
Tzanetakou VKanni TGiatrakou SKatoulis APapadavid ENetea MGet al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152:52-9. [PMID: 26579854]  doi: 10.1001/jamadermatol.2015.3903
28.
Kullenberg TLöfqvist MLeinonen MGoldbach-Mansky ROlivecrona H. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology (Oxford). 2016;55:1499-506. [PMID: 27143789]  doi: 10.1093/rheumatology/kew208
29.
Ogungbenro KHulme SRothwell NHopkins STyrrell PGalea J. Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist. J Pharmacokinet Pharmacodyn. 2016;43:1-12. [PMID: 26476629]
30.
Gueorguieva IClark SRMcMahon CJScarth SRothwell NJTyrrell PJet al. Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. Br J Clin Pharmacol. 2008;65:317-25. [PMID: 17875190]
31.
Goldbach-Mansky RDailey NJCanna SWGelabert AJones JRubin BIet al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med. 2006;355:581-92. [PMID: 16899778]
32.
Goldbach-Mansky R. Blocking interleukin-1 in rheumatic diseases. Ann N Y Acad Sci. 2009;1182:111-23. [PMID: 20074280]  doi: 10.1111/j.1749-6632.2009.05159.x
33.
Omdal RGunnarsson R. The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis—a pilot study. Rheumatol Int. 2005;25:481-4. [PMID: 15071755]
34.
Norheim KBHarboe EGøransson LGOmdal R. Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome—a double blind, randomised clinical trial. PLoS One. 2012;7:e30123. [PMID: 22253903]  doi: 10.1371/journal.pone.0030123
35.
Hoffman HMRosengren SBoyle DLCho JYNayar JMueller JLet al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet. 2004;364:1779-85. [PMID: 15541451]
36.
Cavelti-Weder CFurrer RKeller CBabians-Brunner ASolinger AMGast Het al. Inhibition of IL-1beta improves fatigue in type 2 diabetes [Letter]. Diabetes Care. 2011;34:e158. [PMID: 21949230]  doi: 10.2337/dc11-1196
37.
Roerink MEKnoop HBredie SJHeijnen MJoosten LANetea MGet al. Cytokine inhibition in chronic fatigue syndrome patients: study protocol for a randomized controlled trial. Trials. 2015;16:439. [PMID: 26438161]  doi: 10.1186/s13063-015-0971-z
38.
Sheehan DVLecrubier YSheehan KHAmorim PJanavs JWeiller Eet al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33. [PMID: 9881538]
39.
Kim JShin W. How to do random allocation (randomization). Clin Orthop Surg. 2014;6:103-9. [PMID: 24605197]  doi: 10.4055/cios.2014.6.1.103
40.
Vercoulen JHSwanink CMFennis JFGalama JMvan der Meer JWBleijenberg G. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res. 1994;38:383-92. [PMID: 7965927]
41.
Vercoulen JHAlberst MBleijenberg G. The Checklist Individual Strength (CIS). Gedragstherapie. 1999;32:131-6.
42.
Tummers MKnoop HBleijenberg G. Effectiveness of stepped care for chronic fatigue syndrome: a randomized noninferiority trial. J Consult Clin Psychol. 2010;78:724-31. [PMID: 20873907]  doi: 10.1037/a0020052
43.
Jacobs HMLuttik ATouw-Otten FWde Melker RA. [The sickness impact profile; results of an evaluation study of the Dutch version]. Ned Tijdschr Geneeskd. 1990;134:1950-4. [PMID: 2234151]
44.
Ware JE JrSherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-83. [PMID: 1593914]
45.
Derogatis LRUnger R. Symptom Checklist-90-Revised. In: Weiner IB, Craigshead WE, eds. Corsini Encyclopedia of Psychology, 4th ed. Hoboken, NJ: J Wiley; 2010:1743-4.
46.
Knoop Hvan der Meer JWBleijenberg G. Guided self-instructions for people with chronic fatigue syndrome: randomised controlled trial. Br J Psychiatry. 2008;193:340-1. [PMID: 18827302]  doi: 10.1192/bjp.bp.108.051292
47.
Wiborg JFvan Bussel Jvan Dijk ABleijenberg GKnoop H. Randomised controlled trial of cognitive behaviour therapy delivered in groups of patients with chronic fatigue syndrome. Psychother Psychosom. 2015;84:368-76. [PMID: 26402868]  doi: 10.1159/000438867
48.
Cattaneo AFerrari CUher RBocchio-Chiavetto LRiva MAPariante CMMRC ImmunoPsychiatry Consortium. Absolute measurements of macrophage migration inhibitory factor and interleukin-1-ß mRNA levels accurately predict treatment response in depressed patients. Int J Neuropsychopharmacol. 2016;19. [PMID: 27207917]  doi: 10.1093/ijnp/pyw045
49.
Clark SRMcMahon CJGueorguieva IRowland MScarth SGeorgiou Ret al. Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J Cereb Blood Flow Metab. 2008;28:387-94. [PMID: 17684519]
50.
Greenhalgh ADGalea JDénes ATyrrell PJRothwell NJ. Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br J Pharmacol. 2010;160:153-9.  doi: 10.1111/j.1476-5381.2010.00684.x
51.
van Asseldonk EJStienstra RKoenen TBJoosten LANetea MGTack CJ. Treatment with anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2011;96:2119-26. [PMID: 21508140]  doi: 10.1210/jc.2010-2992
52.
The GKBleijenberg GBuitelaar JKvan der Meer JW. The effect of ondansetron, a 5-HT3 receptor antagonist, in chronic fatigue syndrome: a randomized controlled trial. J Clin Psychiatry. 2010;71:528-33. [PMID: 20122367]  doi: 10.4088/JCP.08m04719whi
53.
Cho HJHotopf MWessely S. The placebo response in the treatment of chronic fatigue syndrome: a systematic review and meta-analysis. Psychosom Med. 2005;67:301-13. [PMID: 15784798]
54.
Vollmer-Conna UFazou CCameron BLi HBrennan CLuck Let al. Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol Med. 2004;34:1289-97. [PMID: 15697055]
55.
Singh KConnors SLMacklin EASmith KDFahey JWTalalay Pet al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci U S A. 2014;111:15550-5. [PMID: 25313065]  doi: 10.1073/pnas.1416940111
56.
Greaney AJMaier NKLeppla SHMoayeri M. Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism. J Leukoc Biol. 2016;99:189-99. [PMID: 26269198]  doi: 10.1189/jlb.3A0415-155RR

Information & Authors

Information

Published In

cover image Annals of Internal Medicine
Annals of Internal Medicine
Volume 166Number 818 April 2017
Pages: 557 - 564

History

Published online: 7 March 2017
Published in issue: 18 April 2017

Keywords

Authors

Affiliations

Megan E. Roerink, MD
From Radboud University Medical Centre, Nijmegen, and University of Amsterdam, Amsterdam, the Netherlands; and University of Colorado Denver, Aurora, Colorado.
Sebastian J.H. Bredie, MD, PhD
From Radboud University Medical Centre, Nijmegen, and University of Amsterdam, Amsterdam, the Netherlands; and University of Colorado Denver, Aurora, Colorado.
Michael Heijnen
From Radboud University Medical Centre, Nijmegen, and University of Amsterdam, Amsterdam, the Netherlands; and University of Colorado Denver, Aurora, Colorado.
Charles A. Dinarello, MD
From Radboud University Medical Centre, Nijmegen, and University of Amsterdam, Amsterdam, the Netherlands; and University of Colorado Denver, Aurora, Colorado.
Hans Knoop, PhD
From Radboud University Medical Centre, Nijmegen, and University of Amsterdam, Amsterdam, the Netherlands; and University of Colorado Denver, Aurora, Colorado.
Jos W.M. Van der Meer, MD, PhD
From Radboud University Medical Centre, Nijmegen, and University of Amsterdam, Amsterdam, the Netherlands; and University of Colorado Denver, Aurora, Colorado.
Note: All authors had full access to the study data, take responsibility for the accuracy of the analysis, and had authority over manuscript preparation and the decision to submit the manuscript for publication. The manuscript is an honest, accurate, and transparent account of the study being reported; no important aspects of the study have been omitted.
Acknowledgment: The authors thank the drug safety monitoring board (Professor George W. Padberg and Professor Paul M.J. Stuyt) and Lianne Vermeeren, Harry R. Koene, Tom Sprong, Joris W.P. Vernooij, Mirjam Tromp, and the ME/CVS Stichting Nederland for their assistance with this study.
Financial Support: By the Interleukin Foundation and an independent donor who wishes to remain anonymous. Anakinra and placebo were provided by the Swedish Orphan Biovitrum.
Disclosures: Prof. Van der Meer reports personal fees from the Swedish Orphan Biovitrum outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M16-2391.
Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that she has no financial relationships or interests to disclose. Darren B. Taichman, MD, PhD, Executive Deputy Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interest to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Catharine B. Stack, PhD, MS, Deputy Editor for Statistics, reports that she has stock holdings in Pfizer and Johnson & Johnson.
Reproducible Research Statement: Study protocol: See the Supplement or www.ncbi.nlm.nih.gov/pubmed/26438161. Statistical code: Available from Dr. Roerink (e-mail, [email protected]). Data set: Portions of the data set are available to approved persons through written agreement with the authors (e-mail, [email protected]). Because participants did not provide informed consent for data sharing, the request will be discussed with our ethics committee to ensure patient privacy.
Corresponding Author: Megan E. Roerink, MD, Department of Internal Medicine, Radboud University Medical Centre, Geert Groteplein Zuid 8, PO Box 9101, 6500 HB Nijmegen, the Netherlands; e-mail, [email protected].
Current Author Addresses: Drs. Roerink and Bredie, Mr. Heijnen, and Prof. Van der Meer: Department of Internal Medicine, Radboud University Medical Centre, Geert Groteplein Zuid 8, PO Box 9101, 6500 HB Nijmegen, the Netherlands.
Dr. Dinarello: University of Colorado Medical Center, 12700 East 19th Avenue, B168, Aurora, CO 80045.
Prof. Knoop: Department of Medical Psychology, Academic Medical Centre (AMC), University of Amsterdam, Postbox 22660 J3 209, 1100 DD Amsterdam, the Netherlands.
Author Contributions: Conception and design: M.E. Roerink, C.A. Dinarello, H. Knoop, J.W.M. Van der Meer.
Analysis and interpretation of the data: M.E. Roerink, C.A. Dinarello, H. Knoop, J.W.M. Van der Meer.
Drafting of the article: M.E. Roerink.
Critical revision of the article for important intellectual content: M.E. Roerink, S.J.H. Bredie, H. Knoop, J.W.M. Van der Meer.
Final approval of the article: M.E. Roerink, S.J.H. Bredie, M. Heijnen, C.A. Dinarello, H. Knoop, J.W.M. Van der Meer.
Provision of study materials or patients: M.E. Roerink, M. Heijnen, H. Knoop.
Statistical expertise: M.E. Roerink, H. Knoop.
Obtaining of funding: H. Knoop, J.W.M. Van der Meer.
Administrative, technical, or logistic support: M.E. Roerink, S.J.H. Bredie, M. Heijnen, H. Knoop.
Collection and assembly of data: M.E. Roerink, M. Heijnen.
This article was published at Annals.org on 7 March 2017.

Metrics & Citations

Metrics

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
Megan E. Roerink, Sebastian J.H. Bredie, Michael Heijnen, et al. Cytokine Inhibition in Patients With Chronic Fatigue Syndrome: A Randomized Trial. Ann Intern Med.2017;166:557-564. [Epub 7 March 2017]. doi:10.7326/M16-2391

View More

Get Access

Login Options:
Purchase

You will be redirected to acponline.org to sign-in to Annals to complete your purchase.

Create your Free Account

You will be redirected to acponline.org to create an account that will provide access to Annals.

View options

PDF/ePub

View PDF/ePub

Related in ACP Journals

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media